nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—ABCC5—Fluorouracil—pancreatic cancer	0.244	0.389	CbGbCtD
Alprostadil—SLCO2B1—Erlotinib—pancreatic cancer	0.177	0.282	CbGbCtD
Alprostadil—ABCC4—Fluorouracil—pancreatic cancer	0.117	0.187	CbGbCtD
Alprostadil—ABCC4—Sunitinib—pancreatic cancer	0.089	0.142	CbGbCtD
Alprostadil—Ecchymosis—Doxorubicin—pancreatic cancer	0.000273	0.00134	CcSEcCtD
Alprostadil—Diabetes mellitus—Epirubicin—pancreatic cancer	0.000273	0.00134	CcSEcCtD
Alprostadil—Anaemia—Fluorouracil—pancreatic cancer	0.000271	0.00133	CcSEcCtD
Alprostadil—Loss of consciousness—Irinotecan—pancreatic cancer	0.000269	0.00132	CcSEcCtD
Alprostadil—Cough—Irinotecan—pancreatic cancer	0.000267	0.00131	CcSEcCtD
Alprostadil—Dyspepsia—Sunitinib—pancreatic cancer	0.000267	0.00131	CcSEcCtD
Alprostadil—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.000267	0.00131	CcSEcCtD
Alprostadil—Renal failure—Docetaxel—pancreatic cancer	0.000266	0.00131	CcSEcCtD
Alprostadil—Myocardial infarction—Docetaxel—pancreatic cancer	0.000266	0.0013	CcSEcCtD
Alprostadil—Hypertension—Irinotecan—pancreatic cancer	0.000265	0.0013	CcSEcCtD
Alprostadil—Abnormal vision—Doxorubicin—pancreatic cancer	0.000264	0.00129	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—pancreatic cancer	0.000262	0.00129	CcSEcCtD
Alprostadil—Cardiac failure congestive—Epirubicin—pancreatic cancer	0.000262	0.00128	CcSEcCtD
Alprostadil—Cough—Gemcitabine—pancreatic cancer	0.00026	0.00128	CcSEcCtD
Alprostadil—Pain—Sunitinib—pancreatic cancer	0.00026	0.00127	CcSEcCtD
Alprostadil—Discomfort—Irinotecan—pancreatic cancer	0.000258	0.00126	CcSEcCtD
Alprostadil—Hypertension—Gemcitabine—pancreatic cancer	0.000258	0.00126	CcSEcCtD
Alprostadil—Asthenia—Tamoxifen—pancreatic cancer	0.000254	0.00125	CcSEcCtD
Alprostadil—Convulsion—Fluorouracil—pancreatic cancer	0.000254	0.00125	CcSEcCtD
Alprostadil—Diabetes mellitus—Doxorubicin—pancreatic cancer	0.000252	0.00124	CcSEcCtD
Alprostadil—Asthenia—Erlotinib—pancreatic cancer	0.000252	0.00123	CcSEcCtD
Alprostadil—Discomfort—Gemcitabine—pancreatic cancer	0.000251	0.00123	CcSEcCtD
Alprostadil—Pruritus—Tamoxifen—pancreatic cancer	0.000251	0.00123	CcSEcCtD
Alprostadil—Oedema—Irinotecan—pancreatic cancer	0.00025	0.00123	CcSEcCtD
Alprostadil—Infection—Irinotecan—pancreatic cancer	0.000248	0.00122	CcSEcCtD
Alprostadil—Pruritus—Erlotinib—pancreatic cancer	0.000248	0.00122	CcSEcCtD
Alprostadil—Discomfort—Fluorouracil—pancreatic cancer	0.000247	0.00121	CcSEcCtD
Alprostadil—Shock—Irinotecan—pancreatic cancer	0.000246	0.00121	CcSEcCtD
Alprostadil—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000245	0.0012	CcSEcCtD
Alprostadil—Haemoglobin—Docetaxel—pancreatic cancer	0.000245	0.0012	CcSEcCtD
Alprostadil—Rhinitis—Docetaxel—pancreatic cancer	0.000244	0.0012	CcSEcCtD
Alprostadil—Oedema—Gemcitabine—pancreatic cancer	0.000244	0.00119	CcSEcCtD
Alprostadil—Haemorrhage—Docetaxel—pancreatic cancer	0.000243	0.00119	CcSEcCtD
Alprostadil—Hypoglycaemia—Epirubicin—pancreatic cancer	0.000243	0.00119	CcSEcCtD
Alprostadil—Diarrhoea—Tamoxifen—pancreatic cancer	0.000243	0.00119	CcSEcCtD
Alprostadil—Hypoaesthesia—Docetaxel—pancreatic cancer	0.000242	0.00119	CcSEcCtD
Alprostadil—Lethargy—Epirubicin—pancreatic cancer	0.000242	0.00119	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—pancreatic cancer	0.000242	0.00119	CcSEcCtD
Alprostadil—Infection—Gemcitabine—pancreatic cancer	0.000242	0.00119	CcSEcCtD
Alprostadil—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000242	0.00119	CcSEcCtD
Alprostadil—Pharyngitis—Docetaxel—pancreatic cancer	0.000242	0.00118	CcSEcCtD
Alprostadil—Body temperature increased—Sunitinib—pancreatic cancer	0.00024	0.00118	CcSEcCtD
Alprostadil—Abdominal pain—Sunitinib—pancreatic cancer	0.00024	0.00118	CcSEcCtD
Alprostadil—Diarrhoea—Erlotinib—pancreatic cancer	0.00024	0.00118	CcSEcCtD
Alprostadil—Oedema—Fluorouracil—pancreatic cancer	0.00024	0.00117	CcSEcCtD
Alprostadil—Urethral disorder—Docetaxel—pancreatic cancer	0.000239	0.00117	CcSEcCtD
Alprostadil—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000239	0.00117	CcSEcCtD
Alprostadil—Infection—Fluorouracil—pancreatic cancer	0.000238	0.00117	CcSEcCtD
Alprostadil—Pain in extremity—Epirubicin—pancreatic cancer	0.000237	0.00116	CcSEcCtD
Alprostadil—Skin disorder—Gemcitabine—pancreatic cancer	0.000237	0.00116	CcSEcCtD
Alprostadil—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000236	0.00115	CcSEcCtD
Alprostadil—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000235	0.00115	CcSEcCtD
Alprostadil—Visual impairment—Docetaxel—pancreatic cancer	0.000235	0.00115	CcSEcCtD
Alprostadil—Dizziness—Tamoxifen—pancreatic cancer	0.000234	0.00115	CcSEcCtD
Alprostadil—Tachycardia—Fluorouracil—pancreatic cancer	0.000234	0.00115	CcSEcCtD
Alprostadil—Hypotension—Irinotecan—pancreatic cancer	0.000234	0.00115	CcSEcCtD
Alprostadil—Dizziness—Erlotinib—pancreatic cancer	0.000232	0.00114	CcSEcCtD
Alprostadil—Hypotension—Gemcitabine—pancreatic cancer	0.000228	0.00112	CcSEcCtD
Alprostadil—Flushing—Docetaxel—pancreatic cancer	0.000226	0.00111	CcSEcCtD
Alprostadil—Cardiac arrest—Epirubicin—pancreatic cancer	0.000226	0.00111	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—pancreatic cancer	0.000225	0.0011	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—pancreatic cancer	0.000224	0.0011	CcSEcCtD
Alprostadil—Hypotension—Fluorouracil—pancreatic cancer	0.000224	0.0011	CcSEcCtD
Alprostadil—Rash—Tamoxifen—pancreatic cancer	0.000224	0.0011	CcSEcCtD
Alprostadil—Dermatitis—Tamoxifen—pancreatic cancer	0.000223	0.0011	CcSEcCtD
Alprostadil—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000222	0.00109	CcSEcCtD
Alprostadil—Headache—Tamoxifen—pancreatic cancer	0.000222	0.00109	CcSEcCtD
Alprostadil—Rash—Erlotinib—pancreatic cancer	0.000221	0.00108	CcSEcCtD
Alprostadil—Dermatitis—Erlotinib—pancreatic cancer	0.000221	0.00108	CcSEcCtD
Alprostadil—Dyspepsia—Irinotecan—pancreatic cancer	0.00022	0.00108	CcSEcCtD
Alprostadil—Headache—Erlotinib—pancreatic cancer	0.00022	0.00108	CcSEcCtD
Alprostadil—Pain in extremity—Doxorubicin—pancreatic cancer	0.00022	0.00108	CcSEcCtD
Alprostadil—Asthenia—Sunitinib—pancreatic cancer	0.000218	0.00107	CcSEcCtD
Alprostadil—Hypokalaemia—Epirubicin—pancreatic cancer	0.000216	0.00106	CcSEcCtD
Alprostadil—Pruritus—Sunitinib—pancreatic cancer	0.000215	0.00105	CcSEcCtD
Alprostadil—Pain—Irinotecan—pancreatic cancer	0.000214	0.00105	CcSEcCtD
Alprostadil—Erythema—Docetaxel—pancreatic cancer	0.000212	0.00104	CcSEcCtD
Alprostadil—Dyspepsia—Fluorouracil—pancreatic cancer	0.000211	0.00103	CcSEcCtD
Alprostadil—Nausea—Tamoxifen—pancreatic cancer	0.000211	0.00103	CcSEcCtD
Alprostadil—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000209	0.00102	CcSEcCtD
Alprostadil—Pain—Gemcitabine—pancreatic cancer	0.000208	0.00102	CcSEcCtD
Alprostadil—Nausea—Erlotinib—pancreatic cancer	0.000208	0.00102	CcSEcCtD
Alprostadil—Diarrhoea—Sunitinib—pancreatic cancer	0.000208	0.00102	CcSEcCtD
Alprostadil—Feeling abnormal—Irinotecan—pancreatic cancer	0.000206	0.00101	CcSEcCtD
Alprostadil—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000206	0.00101	CcSEcCtD
Alprostadil—Influenza—Epirubicin—pancreatic cancer	0.000205	0.00101	CcSEcCtD
Alprostadil—Back pain—Docetaxel—pancreatic cancer	0.000205	0.001	CcSEcCtD
Alprostadil—Pain—Fluorouracil—pancreatic cancer	0.000205	0.001	CcSEcCtD
Alprostadil—Muscle spasms—Docetaxel—pancreatic cancer	0.000204	0.000999	CcSEcCtD
Alprostadil—Dizziness—Sunitinib—pancreatic cancer	0.000201	0.000985	CcSEcCtD
Alprostadil—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000201	0.000984	CcSEcCtD
Alprostadil—Hypokalaemia—Doxorubicin—pancreatic cancer	0.0002	0.00098	CcSEcCtD
Alprostadil—Body temperature increased—Irinotecan—pancreatic cancer	0.000198	0.000969	CcSEcCtD
Alprostadil—Abdominal pain—Irinotecan—pancreatic cancer	0.000198	0.000969	CcSEcCtD
Alprostadil—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000197	0.000968	CcSEcCtD
Alprostadil—Bronchitis—Epirubicin—pancreatic cancer	0.000197	0.000967	CcSEcCtD
Alprostadil—Anaemia—Docetaxel—pancreatic cancer	0.000196	0.00096	CcSEcCtD
Alprostadil—Body temperature increased—Gemcitabine—pancreatic cancer	0.000193	0.000944	CcSEcCtD
Alprostadil—Rash—Sunitinib—pancreatic cancer	0.000191	0.000939	CcSEcCtD
Alprostadil—Dermatitis—Sunitinib—pancreatic cancer	0.000191	0.000938	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000191	0.000935	CcSEcCtD
Alprostadil—Headache—Sunitinib—pancreatic cancer	0.00019	0.000933	CcSEcCtD
Alprostadil—Syncope—Docetaxel—pancreatic cancer	0.00019	0.000932	CcSEcCtD
Alprostadil—Influenza—Doxorubicin—pancreatic cancer	0.00019	0.00093	CcSEcCtD
Alprostadil—Pollakiuria—Epirubicin—pancreatic cancer	0.000189	0.000929	CcSEcCtD
Alprostadil—Body temperature increased—Fluorouracil—pancreatic cancer	0.000189	0.000929	CcSEcCtD
Alprostadil—Loss of consciousness—Docetaxel—pancreatic cancer	0.000186	0.000913	CcSEcCtD
Alprostadil—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000185	0.000907	CcSEcCtD
Alprostadil—Cough—Docetaxel—pancreatic cancer	0.000185	0.000906	CcSEcCtD
Alprostadil—Convulsion—Docetaxel—pancreatic cancer	0.000184	0.0009	CcSEcCtD
Alprostadil—Hypertension—Docetaxel—pancreatic cancer	0.000183	0.000897	CcSEcCtD
Alprostadil—Bronchitis—Doxorubicin—pancreatic cancer	0.000182	0.000895	CcSEcCtD
Alprostadil—Nausea—Sunitinib—pancreatic cancer	0.00018	0.000884	CcSEcCtD
Alprostadil—Renal failure—Epirubicin—pancreatic cancer	0.00018	0.000881	CcSEcCtD
Alprostadil—Asthenia—Irinotecan—pancreatic cancer	0.000179	0.00088	CcSEcCtD
Alprostadil—Urinary tract infection—Epirubicin—pancreatic cancer	0.000178	0.000871	CcSEcCtD
Alprostadil—Dry mouth—Docetaxel—pancreatic cancer	0.000176	0.000865	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000176	0.000865	CcSEcCtD
Alprostadil—Pollakiuria—Doxorubicin—pancreatic cancer	0.000175	0.000859	CcSEcCtD
Alprostadil—Asthenia—Gemcitabine—pancreatic cancer	0.000175	0.000857	CcSEcCtD
Alprostadil—Haematuria—Epirubicin—pancreatic cancer	0.000174	0.000855	CcSEcCtD
Alprostadil—Oedema—Docetaxel—pancreatic cancer	0.000173	0.000848	CcSEcCtD
Alprostadil—Pruritus—Gemcitabine—pancreatic cancer	0.000172	0.000845	CcSEcCtD
Alprostadil—Infection—Docetaxel—pancreatic cancer	0.000172	0.000842	CcSEcCtD
Alprostadil—Sinusitis—Epirubicin—pancreatic cancer	0.000172	0.000841	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000171	0.000839	CcSEcCtD
Alprostadil—Diarrhoea—Irinotecan—pancreatic cancer	0.000171	0.000839	CcSEcCtD
Alprostadil—Shock—Docetaxel—pancreatic cancer	0.00017	0.000834	CcSEcCtD
Alprostadil—Pruritus—Fluorouracil—pancreatic cancer	0.000169	0.000831	CcSEcCtD
Alprostadil—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000169	0.00083	CcSEcCtD
Alprostadil—Tachycardia—Docetaxel—pancreatic cancer	0.000169	0.000827	CcSEcCtD
Alprostadil—Skin disorder—Docetaxel—pancreatic cancer	0.000168	0.000823	CcSEcCtD
Alprostadil—Bradycardia—Epirubicin—pancreatic cancer	0.000167	0.000819	CcSEcCtD
Alprostadil—Diarrhoea—Gemcitabine—pancreatic cancer	0.000167	0.000817	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—pancreatic cancer	0.000166	0.000815	CcSEcCtD
Alprostadil—Dizziness—Irinotecan—pancreatic cancer	0.000165	0.000811	CcSEcCtD
Alprostadil—Haemoglobin—Epirubicin—pancreatic cancer	0.000165	0.000809	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—pancreatic cancer	0.000165	0.000807	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000164	0.000806	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—pancreatic cancer	0.000164	0.000805	CcSEcCtD
Alprostadil—Diarrhoea—Fluorouracil—pancreatic cancer	0.000164	0.000804	CcSEcCtD
Alprostadil—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000163	0.000801	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—pancreatic cancer	0.000163	0.000799	CcSEcCtD
Alprostadil—Hypotension—Docetaxel—pancreatic cancer	0.000162	0.000792	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—pancreatic cancer	0.000161	0.000791	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—pancreatic cancer	0.000161	0.000789	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—pancreatic cancer	0.000159	0.000778	CcSEcCtD
Alprostadil—Dizziness—Fluorouracil—pancreatic cancer	0.000158	0.000777	CcSEcCtD
Alprostadil—Visual impairment—Epirubicin—pancreatic cancer	0.000158	0.000776	CcSEcCtD
Alprostadil—Rash—Irinotecan—pancreatic cancer	0.000158	0.000773	CcSEcCtD
Alprostadil—Dermatitis—Irinotecan—pancreatic cancer	0.000158	0.000773	CcSEcCtD
Alprostadil—Headache—Irinotecan—pancreatic cancer	0.000157	0.000768	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—pancreatic cancer	0.000155	0.000758	CcSEcCtD
Alprostadil—Rash—Gemcitabine—pancreatic cancer	0.000154	0.000753	CcSEcCtD
Alprostadil—Dermatitis—Gemcitabine—pancreatic cancer	0.000153	0.000753	CcSEcCtD
Alprostadil—Haemoglobin—Doxorubicin—pancreatic cancer	0.000153	0.000748	CcSEcCtD
Alprostadil—Headache—Gemcitabine—pancreatic cancer	0.000153	0.000748	CcSEcCtD
Alprostadil—Flushing—Epirubicin—pancreatic cancer	0.000152	0.000747	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—pancreatic cancer	0.000152	0.000747	CcSEcCtD
Alprostadil—Dyspepsia—Docetaxel—pancreatic cancer	0.000152	0.000746	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—pancreatic cancer	0.000152	0.000745	CcSEcCtD
Alprostadil—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000151	0.000741	CcSEcCtD
Alprostadil—Rash—Fluorouracil—pancreatic cancer	0.000151	0.000741	CcSEcCtD
Alprostadil—Dermatitis—Fluorouracil—pancreatic cancer	0.000151	0.00074	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—pancreatic cancer	0.000151	0.000739	CcSEcCtD
Alprostadil—Headache—Fluorouracil—pancreatic cancer	0.00015	0.000736	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—pancreatic cancer	0.000149	0.00073	CcSEcCtD
Alprostadil—Nausea—Irinotecan—pancreatic cancer	0.000149	0.000728	CcSEcCtD
Alprostadil—Pain—Docetaxel—pancreatic cancer	0.000148	0.000725	CcSEcCtD
Alprostadil—Visual impairment—Doxorubicin—pancreatic cancer	0.000146	0.000718	CcSEcCtD
Alprostadil—Nausea—Gemcitabine—pancreatic cancer	0.000145	0.00071	CcSEcCtD
Alprostadil—Erythema—Epirubicin—pancreatic cancer	0.000143	0.000701	CcSEcCtD
Alprostadil—Feeling abnormal—Docetaxel—pancreatic cancer	0.000142	0.000699	CcSEcCtD
Alprostadil—Nausea—Fluorouracil—pancreatic cancer	0.000142	0.000698	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—pancreatic cancer	0.000141	0.000691	CcSEcCtD
Alprostadil—Nervousness—Epirubicin—pancreatic cancer	0.000139	0.00068	CcSEcCtD
Alprostadil—Back pain—Epirubicin—pancreatic cancer	0.000138	0.000678	CcSEcCtD
Alprostadil—Muscle spasms—Epirubicin—pancreatic cancer	0.000137	0.000674	CcSEcCtD
Alprostadil—Body temperature increased—Docetaxel—pancreatic cancer	0.000137	0.00067	CcSEcCtD
Alprostadil—Abdominal pain—Docetaxel—pancreatic cancer	0.000137	0.00067	CcSEcCtD
Alprostadil—Erythema—Doxorubicin—pancreatic cancer	0.000132	0.000648	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—pancreatic cancer	0.000132	0.000648	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—pancreatic cancer	0.000128	0.00063	CcSEcCtD
Alprostadil—Syncope—Epirubicin—pancreatic cancer	0.000128	0.000628	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—pancreatic cancer	0.000128	0.000627	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—pancreatic cancer	0.000127	0.000623	CcSEcCtD
Alprostadil—Loss of consciousness—Epirubicin—pancreatic cancer	0.000126	0.000616	CcSEcCtD
Alprostadil—Cough—Epirubicin—pancreatic cancer	0.000125	0.000611	CcSEcCtD
Alprostadil—Asthenia—Docetaxel—pancreatic cancer	0.000124	0.000608	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—pancreatic cancer	0.000124	0.000607	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—pancreatic cancer	0.000123	0.000605	CcSEcCtD
Alprostadil—Pruritus—Docetaxel—pancreatic cancer	0.000122	0.0006	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—pancreatic cancer	0.000122	0.000599	CcSEcCtD
Alprostadil—Discomfort—Epirubicin—pancreatic cancer	0.00012	0.000589	CcSEcCtD
Alprostadil—Dry mouth—Epirubicin—pancreatic cancer	0.000119	0.000583	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—pancreatic cancer	0.000119	0.000581	CcSEcCtD
Alprostadil—Diarrhoea—Docetaxel—pancreatic cancer	0.000118	0.00058	CcSEcCtD
Alprostadil—Oedema—Epirubicin—pancreatic cancer	0.000117	0.000572	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000116	0.00057	CcSEcCtD
Alprostadil—Infection—Epirubicin—pancreatic cancer	0.000116	0.000568	CcSEcCtD
Alprostadil—Cough—Doxorubicin—pancreatic cancer	0.000115	0.000566	CcSEcCtD
Alprostadil—Shock—Epirubicin—pancreatic cancer	0.000115	0.000563	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—pancreatic cancer	0.000115	0.000562	CcSEcCtD
Alprostadil—Dizziness—Docetaxel—pancreatic cancer	0.000114	0.000561	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000114	0.00056	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—pancreatic cancer	0.000114	0.00056	CcSEcCtD
Alprostadil—Tachycardia—Epirubicin—pancreatic cancer	0.000114	0.000558	CcSEcCtD
Alprostadil—Skin disorder—Epirubicin—pancreatic cancer	0.000113	0.000555	CcSEcCtD
Alprostadil—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000113	0.000553	CcSEcCtD
Alprostadil—Discomfort—Doxorubicin—pancreatic cancer	0.000111	0.000545	CcSEcCtD
Alprostadil—Dry mouth—Doxorubicin—pancreatic cancer	0.00011	0.00054	CcSEcCtD
Alprostadil—Rash—Docetaxel—pancreatic cancer	0.000109	0.000535	CcSEcCtD
Alprostadil—Hypotension—Epirubicin—pancreatic cancer	0.000109	0.000534	CcSEcCtD
Alprostadil—Dermatitis—Docetaxel—pancreatic cancer	0.000109	0.000534	CcSEcCtD
Alprostadil—Headache—Docetaxel—pancreatic cancer	0.000108	0.000531	CcSEcCtD
Alprostadil—Oedema—Doxorubicin—pancreatic cancer	0.000108	0.000529	CcSEcCtD
Alprostadil—Infection—Doxorubicin—pancreatic cancer	0.000107	0.000526	CcSEcCtD
Alprostadil—Shock—Doxorubicin—pancreatic cancer	0.000106	0.000521	CcSEcCtD
Alprostadil—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000106	0.000518	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—pancreatic cancer	0.000105	0.000516	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—pancreatic cancer	0.000105	0.000514	CcSEcCtD
Alprostadil—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000104	0.000511	CcSEcCtD
Alprostadil—Nausea—Docetaxel—pancreatic cancer	0.000103	0.000504	CcSEcCtD
Alprostadil—Dyspepsia—Epirubicin—pancreatic cancer	0.000103	0.000503	CcSEcCtD
Alprostadil—Hypotension—Doxorubicin—pancreatic cancer	0.000101	0.000494	CcSEcCtD
Alprostadil—Pain—Epirubicin—pancreatic cancer	9.97e-05	0.000489	CcSEcCtD
Alprostadil—Feeling abnormal—Epirubicin—pancreatic cancer	9.61e-05	0.000471	CcSEcCtD
Alprostadil—Dyspepsia—Doxorubicin—pancreatic cancer	9.5e-05	0.000466	CcSEcCtD
Alprostadil—Pain—Doxorubicin—pancreatic cancer	9.23e-05	0.000452	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—pancreatic cancer	9.22e-05	0.000452	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—pancreatic cancer	9.22e-05	0.000452	CcSEcCtD
Alprostadil—Feeling abnormal—Doxorubicin—pancreatic cancer	8.89e-05	0.000436	CcSEcCtD
Alprostadil—Abdominal pain—Doxorubicin—pancreatic cancer	8.53e-05	0.000418	CcSEcCtD
Alprostadil—Body temperature increased—Doxorubicin—pancreatic cancer	8.53e-05	0.000418	CcSEcCtD
Alprostadil—Asthenia—Epirubicin—pancreatic cancer	8.37e-05	0.00041	CcSEcCtD
Alprostadil—Pruritus—Epirubicin—pancreatic cancer	8.25e-05	0.000405	CcSEcCtD
Alprostadil—Diarrhoea—Epirubicin—pancreatic cancer	7.98e-05	0.000391	CcSEcCtD
Alprostadil—Asthenia—Doxorubicin—pancreatic cancer	7.74e-05	0.00038	CcSEcCtD
Alprostadil—Dizziness—Epirubicin—pancreatic cancer	7.71e-05	0.000378	CcSEcCtD
Alprostadil—Pruritus—Doxorubicin—pancreatic cancer	7.63e-05	0.000374	CcSEcCtD
Alprostadil—Diarrhoea—Doxorubicin—pancreatic cancer	7.38e-05	0.000362	CcSEcCtD
Alprostadil—Rash—Epirubicin—pancreatic cancer	7.35e-05	0.000361	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—pancreatic cancer	7.35e-05	0.00036	CcSEcCtD
Alprostadil—Headache—Epirubicin—pancreatic cancer	7.31e-05	0.000358	CcSEcCtD
Alprostadil—Dizziness—Doxorubicin—pancreatic cancer	7.13e-05	0.00035	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—CCK—pancreatic cancer	7.07e-05	0.000417	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GCG—pancreatic cancer	7.07e-05	0.000417	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCK—pancreatic cancer	7.07e-05	0.000417	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—DPYD—pancreatic cancer	6.97e-05	0.000412	CbGpPWpGaD
Alprostadil—Nausea—Epirubicin—pancreatic cancer	6.93e-05	0.00034	CcSEcCtD
Alprostadil—PTGIR—Signaling Pathways—CNR2—pancreatic cancer	6.89e-05	0.000407	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CNR2—pancreatic cancer	6.89e-05	0.000407	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GLP1R—pancreatic cancer	6.89e-05	0.000407	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GLP1R—pancreatic cancer	6.89e-05	0.000407	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCL8—pancreatic cancer	6.88e-05	0.000406	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CXCL8—pancreatic cancer	6.88e-05	0.000406	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.88e-05	0.000406	CbGpPWpGaD
Alprostadil—Rash—Doxorubicin—pancreatic cancer	6.8e-05	0.000334	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—pancreatic cancer	6.8e-05	0.000333	CcSEcCtD
Alprostadil—PTGIR—Signaling Pathways—CCKAR—pancreatic cancer	6.78e-05	0.0004	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCKAR—pancreatic cancer	6.78e-05	0.0004	CbGpPWpGaD
Alprostadil—Headache—Doxorubicin—pancreatic cancer	6.76e-05	0.000331	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—AGTR1—pancreatic cancer	6.74e-05	0.000398	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STK11—pancreatic cancer	6.65e-05	0.000392	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SLC2A2—pancreatic cancer	6.61e-05	0.00039	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—JAG2—pancreatic cancer	6.57e-05	0.000388	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—JAG2—pancreatic cancer	6.57e-05	0.000388	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MEN1—pancreatic cancer	6.48e-05	0.000382	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MEN1—pancreatic cancer	6.48e-05	0.000382	CbGpPWpGaD
Alprostadil—ABCC5—Disease—JAG1—pancreatic cancer	6.44e-05	0.00038	CbGpPWpGaD
Alprostadil—Nausea—Doxorubicin—pancreatic cancer	6.41e-05	0.000314	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—PIK3CB—pancreatic cancer	6.41e-05	0.000378	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CD—pancreatic cancer	6.24e-05	0.000369	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SHH—pancreatic cancer	6.18e-05	0.000365	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SHH—pancreatic cancer	6.18e-05	0.000365	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH4—pancreatic cancer	6.14e-05	0.000363	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH4—pancreatic cancer	6.14e-05	0.000363	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CD44—pancreatic cancer	6.12e-05	0.000361	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IAPP—pancreatic cancer	6.1e-05	0.00036	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IAPP—pancreatic cancer	6.1e-05	0.00036	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HSPA1A—pancreatic cancer	6.07e-05	0.000358	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.99e-05	0.000354	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	5.94e-05	0.000351	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTHLH—pancreatic cancer	5.86e-05	0.000346	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTHLH—pancreatic cancer	5.86e-05	0.000346	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTCH1—pancreatic cancer	5.86e-05	0.000346	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTCH1—pancreatic cancer	5.86e-05	0.000346	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SMAD4—pancreatic cancer	5.82e-05	0.000344	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	5.78e-05	0.000341	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCL8—pancreatic cancer	5.76e-05	0.00034	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HES1—pancreatic cancer	5.68e-05	0.000336	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PLAU—pancreatic cancer	5.6e-05	0.000331	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CB—pancreatic cancer	5.44e-05	0.000321	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SST—pancreatic cancer	5.36e-05	0.000316	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SST—pancreatic cancer	5.36e-05	0.000316	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	5.31e-05	0.000313	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CG—pancreatic cancer	5.28e-05	0.000312	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CG—pancreatic cancer	5.28e-05	0.000312	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—JAG1—pancreatic cancer	5.24e-05	0.00031	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—JAG1—pancreatic cancer	5.24e-05	0.00031	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CXCL8—pancreatic cancer	5.23e-05	0.000309	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH3—pancreatic cancer	5.22e-05	0.000308	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH3—pancreatic cancer	5.22e-05	0.000308	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—SRC—pancreatic cancer	5.13e-05	0.000303	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CD44—pancreatic cancer	5.12e-05	0.000302	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VEGFA—pancreatic cancer	5e-05	0.000295	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CG—pancreatic cancer	4.98e-05	0.000294	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TERT—pancreatic cancer	4.98e-05	0.000294	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CNR1—pancreatic cancer	4.94e-05	0.000292	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CNR1—pancreatic cancer	4.94e-05	0.000292	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NRAS—pancreatic cancer	4.94e-05	0.000292	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—EGF—pancreatic cancer	4.93e-05	0.000291	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GCG—pancreatic cancer	4.91e-05	0.00029	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SMAD4—pancreatic cancer	4.83e-05	0.000285	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CG—pancreatic cancer	4.8e-05	0.000283	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CG—pancreatic cancer	4.8e-05	0.000283	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GCG—pancreatic cancer	4.78e-05	0.000282	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GCG—pancreatic cancer	4.78e-05	0.000282	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HIF1A—pancreatic cancer	4.76e-05	0.000281	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TSC2—pancreatic cancer	4.75e-05	0.000281	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HES1—pancreatic cancer	4.71e-05	0.000278	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APOE—pancreatic cancer	4.65e-05	0.000275	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CD—pancreatic cancer	4.65e-05	0.000274	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CD—pancreatic cancer	4.65e-05	0.000274	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—STK11—pancreatic cancer	4.62e-05	0.000273	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TGFB1—pancreatic cancer	4.59e-05	0.000271	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGTR1—pancreatic cancer	4.56e-05	0.000269	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGTR1—pancreatic cancer	4.56e-05	0.000269	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KDR—pancreatic cancer	4.56e-05	0.000269	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	4.52e-05	0.000267	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STK11—pancreatic cancer	4.49e-05	0.000265	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STK11—pancreatic cancer	4.49e-05	0.000265	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CD—pancreatic cancer	4.38e-05	0.000259	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NFKBIA—pancreatic cancer	4.33e-05	0.000256	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOTCH1—pancreatic cancer	4.29e-05	0.000253	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—KRAS—pancreatic cancer	4.25e-05	0.000251	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CD—pancreatic cancer	4.22e-05	0.000249	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CD—pancreatic cancer	4.22e-05	0.000249	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CG—pancreatic cancer	4.2e-05	0.000248	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—NRAS—pancreatic cancer	4.2e-05	0.000248	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGF—pancreatic cancer	4.15e-05	0.000245	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TERT—pancreatic cancer	4.13e-05	0.000244	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CB—pancreatic cancer	4.05e-05	0.000239	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CB—pancreatic cancer	4.05e-05	0.000239	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TYMS—pancreatic cancer	3.97e-05	0.000234	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HIF1A—pancreatic cancer	3.95e-05	0.000233	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TSC2—pancreatic cancer	3.94e-05	0.000233	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SMAD4—pancreatic cancer	3.93e-05	0.000232	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SMAD4—pancreatic cancer	3.93e-05	0.000232	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CA—pancreatic cancer	3.91e-05	0.000231	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL8—pancreatic cancer	3.89e-05	0.00023	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL8—pancreatic cancer	3.89e-05	0.00023	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOE—pancreatic cancer	3.86e-05	0.000228	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HES1—pancreatic cancer	3.84e-05	0.000227	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HES1—pancreatic cancer	3.84e-05	0.000227	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—pancreatic cancer	3.82e-05	0.000226	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CB—pancreatic cancer	3.82e-05	0.000225	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—pancreatic cancer	3.78e-05	0.000223	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	3.69e-05	0.000218	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CD—pancreatic cancer	3.69e-05	0.000218	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CB—pancreatic cancer	3.68e-05	0.000217	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CB—pancreatic cancer	3.68e-05	0.000217	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.65e-05	0.000216	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—pancreatic cancer	3.61e-05	0.000213	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—KRAS—pancreatic cancer	3.61e-05	0.000213	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOTCH1—pancreatic cancer	3.56e-05	0.00021	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL8—pancreatic cancer	3.53e-05	0.000209	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCL8—pancreatic cancer	3.53e-05	0.000209	CbGpPWpGaD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—pancreatic cancer	3.48e-05	1	CrCbGaD
Alprostadil—ABCC5—Disease—EGF—pancreatic cancer	3.44e-05	0.000203	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TERT—pancreatic cancer	3.36e-05	0.000199	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TERT—pancreatic cancer	3.36e-05	0.000199	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CA—pancreatic cancer	3.32e-05	0.000196	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOE—pancreatic cancer	3.23e-05	0.000191	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HIF1A—pancreatic cancer	3.22e-05	0.00019	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HIF1A—pancreatic cancer	3.22e-05	0.00019	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CB—pancreatic cancer	3.22e-05	0.00019	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TSC2—pancreatic cancer	3.21e-05	0.000189	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TSC2—pancreatic cancer	3.21e-05	0.000189	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—pancreatic cancer	3.19e-05	0.000188	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOE—pancreatic cancer	3.14e-05	0.000185	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOE—pancreatic cancer	3.14e-05	0.000185	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL8—pancreatic cancer	3.09e-05	0.000182	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KDR—pancreatic cancer	3.08e-05	0.000182	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KDR—pancreatic cancer	3.08e-05	0.000182	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—pancreatic cancer	3.07e-05	0.000181	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SRC—pancreatic cancer	3.06e-05	0.000181	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CD—pancreatic cancer	3.06e-05	0.000181	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—pancreatic cancer	2.98e-05	0.000176	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—pancreatic cancer	2.98e-05	0.000176	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CASP3—pancreatic cancer	2.96e-05	0.000175	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NRAS—pancreatic cancer	2.94e-05	0.000174	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NFKBIA—pancreatic cancer	2.93e-05	0.000173	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NFKBIA—pancreatic cancer	2.93e-05	0.000173	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CG—pancreatic cancer	2.92e-05	0.000172	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH1—pancreatic cancer	2.9e-05	0.000171	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH1—pancreatic cancer	2.9e-05	0.000171	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCND1—pancreatic cancer	2.88e-05	0.00017	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CTNNB1—pancreatic cancer	2.85e-05	0.000168	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CG—pancreatic cancer	2.83e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CG—pancreatic cancer	2.83e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—NRAS—pancreatic cancer	2.83e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—NRAS—pancreatic cancer	2.83e-05	0.000167	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARG—pancreatic cancer	2.81e-05	0.000166	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGF—pancreatic cancer	2.8e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGF—pancreatic cancer	2.8e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—pancreatic cancer	2.79e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTEN—pancreatic cancer	2.78e-05	0.000164	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TGFB1—pancreatic cancer	2.74e-05	0.000162	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—pancreatic cancer	2.71e-05	0.00016	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CB—pancreatic cancer	2.67e-05	0.000157	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—pancreatic cancer	2.64e-05	0.000156	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—pancreatic cancer	2.58e-05	0.000152	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—pancreatic cancer	2.58e-05	0.000152	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SRC—pancreatic cancer	2.58e-05	0.000152	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CD—pancreatic cancer	2.56e-05	0.000151	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KRAS—pancreatic cancer	2.53e-05	0.00015	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—pancreatic cancer	2.51e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CD—pancreatic cancer	2.49e-05	0.000147	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CD—pancreatic cancer	2.49e-05	0.000147	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STAT3—pancreatic cancer	2.48e-05	0.000147	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NRAS—pancreatic cancer	2.48e-05	0.000146	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.47e-05	0.000146	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.47e-05	0.000146	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KRAS—pancreatic cancer	2.44e-05	0.000144	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KRAS—pancreatic cancer	2.44e-05	0.000144	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CTNNB1—pancreatic cancer	2.36e-05	0.00014	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CA—pancreatic cancer	2.33e-05	0.000137	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—pancreatic cancer	2.31e-05	0.000136	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTEN—pancreatic cancer	2.3e-05	0.000136	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFB1—pancreatic cancer	2.3e-05	0.000136	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—pancreatic cancer	2.26e-05	0.000133	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—pancreatic cancer	2.25e-05	0.000133	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CA—pancreatic cancer	2.24e-05	0.000132	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.24e-05	0.000132	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CB—pancreatic cancer	2.23e-05	0.000132	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—pancreatic cancer	2.21e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CB—pancreatic cancer	2.17e-05	0.000128	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CB—pancreatic cancer	2.17e-05	0.000128	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—pancreatic cancer	2.15e-05	0.000127	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SRC—pancreatic cancer	2.14e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KRAS—pancreatic cancer	2.13e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL8—pancreatic cancer	2.09e-05	0.000123	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL8—pancreatic cancer	2.09e-05	0.000123	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—pancreatic cancer	2.07e-05	0.000122	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—pancreatic cancer	2.07e-05	0.000122	CbGpPWpGaD
Alprostadil—ABCC5—Disease—STAT3—pancreatic cancer	2.06e-05	0.000122	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NRAS—pancreatic cancer	2.06e-05	0.000121	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—pancreatic cancer	2.02e-05	0.000119	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—pancreatic cancer	2.02e-05	0.000119	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CASP3—pancreatic cancer	2e-05	0.000118	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CASP3—pancreatic cancer	2e-05	0.000118	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CA—pancreatic cancer	1.96e-05	0.000116	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCND1—pancreatic cancer	1.94e-05	0.000115	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCND1—pancreatic cancer	1.94e-05	0.000115	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTEN—pancreatic cancer	1.93e-05	0.000114	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CTNNB1—pancreatic cancer	1.93e-05	0.000114	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CTNNB1—pancreatic cancer	1.93e-05	0.000114	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—pancreatic cancer	1.92e-05	0.000113	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFB1—pancreatic cancer	1.91e-05	0.000113	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—pancreatic cancer	1.9e-05	0.000112	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—pancreatic cancer	1.9e-05	0.000112	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—pancreatic cancer	1.89e-05	0.000111	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—pancreatic cancer	1.89e-05	0.000111	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTEN—pancreatic cancer	1.88e-05	0.000111	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTEN—pancreatic cancer	1.88e-05	0.000111	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—pancreatic cancer	1.87e-05	0.000111	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—pancreatic cancer	1.83e-05	0.000108	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—pancreatic cancer	1.83e-05	0.000108	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—pancreatic cancer	1.81e-05	0.000107	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KRAS—pancreatic cancer	1.77e-05	0.000104	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SRC—pancreatic cancer	1.74e-05	0.000103	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SRC—pancreatic cancer	1.74e-05	0.000103	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—pancreatic cancer	1.7e-05	0.0001	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—pancreatic cancer	1.7e-05	0.0001	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STAT3—pancreatic cancer	1.68e-05	9.91e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STAT3—pancreatic cancer	1.68e-05	9.91e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NRAS—pancreatic cancer	1.67e-05	9.89e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NRAS—pancreatic cancer	1.67e-05	9.89e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CA—pancreatic cancer	1.63e-05	9.6e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—pancreatic cancer	1.6e-05	9.45e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—pancreatic cancer	1.56e-05	9.21e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—pancreatic cancer	1.56e-05	9.21e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFB1—pancreatic cancer	1.56e-05	9.19e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFB1—pancreatic cancer	1.56e-05	9.19e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—pancreatic cancer	1.53e-05	9.01e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—pancreatic cancer	1.53e-05	9.01e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—pancreatic cancer	1.5e-05	8.88e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KRAS—pancreatic cancer	1.44e-05	8.51e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KRAS—pancreatic cancer	1.44e-05	8.51e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CA—pancreatic cancer	1.36e-05	8.04e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—pancreatic cancer	1.33e-05	7.84e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CA—pancreatic cancer	1.32e-05	7.82e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CA—pancreatic cancer	1.32e-05	7.82e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—pancreatic cancer	1.28e-05	7.56e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—pancreatic cancer	1.28e-05	7.56e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—pancreatic cancer	1.22e-05	7.23e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—pancreatic cancer	1.22e-05	7.23e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—pancreatic cancer	1.11e-05	6.57e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—pancreatic cancer	1.08e-05	6.39e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—pancreatic cancer	1.08e-05	6.39e-05	CbGpPWpGaD
